You are currently viewing a new version of our website. To view the old version click .

Current Oncology, Volume 28, Issue 1

February 2021 - 98 articles

Cover Story: Lung cancer is the leading cause of cancer-related death in the world, largely due to late stage at diagnosis. Approximately 70% of lung cancer patients in Canada are diagnosed with late-stage disease, emphasizing a need to detect lung cancer earlier. International literature has shown long diagnostic delays in primary care; however, in Canada, little is known about how lung cancer patients move through primary care to get to a respiratory specialist for definitive diagnosis. In this issue, authors identify and describe common lung cancer diagnostic pathways in primary care from first presentation to specialist referral and suggest sources of diagnostic delay combined with potential improvement strategies. View this paper.
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (98)

  • Brief Report
  • Open Access
8 Citations
3,734 Views
5 Pages

5 February 2021

Background: Myxofibrosarcoma is a type of soft-tissue sarcoma that is associated with high rates of local recurrence and distant metastases. The first-line treatment for metastatic soft-tissue sarcoma has conventionally been doxorubicin-based. Recent...

  • Article
  • Open Access
7 Citations
4,871 Views
13 Pages

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients

  • Xiaofu Zhu,
  • Susan Dent,
  • Lise Paquet,
  • Tinghua Zhang,
  • Daniel Tesolin,
  • Nadine Graham,
  • Olexiy Aseyev and
  • Xinni Song

4 February 2021

Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic p...

  • Review
  • Open Access
41 Citations
9,639 Views
17 Pages

Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists

  • Angel A. T. Uchiyama,
  • Pedro A. I. A. Silva,
  • Moisés S. M. Lopes,
  • Cheng T. Yen,
  • Eliza D. Ricardo,
  • Taciana Mutão,
  • Jefferson R. Pimenta,
  • Larissa M. Machado,
  • Denis S. Shimba and
  • Renata D. Peixoto

3 February 2021

Proton pump inhibitors (PPIs) are the most commonly used anti-acid drugs worldwide, including among cancer patients. However, drug-drug interactions between PPIs and other agents may lead to decreased drug absorption with possible reduced therapeutic...

  • Article
  • Open Access
7 Citations
4,313 Views
16 Pages

2 February 2021

Implementation of survivorship care plans remain a challenge. This quality improvement initiative aims to integrate personalized treatment plans (PTP) and care plans (PCP) into the existing workflow for breast cancer (BC) patients. Methods: Phase 1 w...

  • Case Report
  • Open Access
20 Citations
3,817 Views
10 Pages

Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD

  • Rebekah Rittberg,
  • Craig Harlos,
  • Heidi Rothenmund,
  • Anirban Das,
  • Uri Tabori,
  • Namita Sinha,
  • Harminder Singh,
  • Bernie Chodirker and
  • Christina A. Kim

1 February 2021

Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive hereditary cancer syndrome due to biallelic germline mutation involving one of the four DNA mismatch repair genes. Here we present a case of a young female with CMMRD, ho...

  • Study Protocol
  • Open Access
11 Citations
5,219 Views
14 Pages

Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma

  • Masazumi Fujii,
  • Masao Kobayakawa,
  • Kiyoshi Saito,
  • Akihiro Inano,
  • Akio Morita,
  • Mitsuhiro Hasegawa,
  • Akitake Mukasa,
  • Takafumi Mitsuhara,
  • Takeo Goto and
  • Shigeru Yamaguchi
  • + 7 authors

31 January 2021

Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s gr...

  • Article
  • Open Access
7 Citations
3,225 Views
10 Pages

31 January 2021

Radiation oncology (RO) teaching in undergraduate medical education (UME) is lacking worldwide with potentially detrimental effects on medical student career choices and patient care. The objective of this scoping review is to examine the extent of p...

  • Case Report
  • Open Access
1 Citations
4,169 Views
7 Pages

CSF Rhinorrhea: A Rare Clinical Presentation of Choroid Plexus Papilloma

  • Layth Mula-Hussain,
  • Julia Malone,
  • Marlise P. dos Santos,
  • John Sinclair and
  • Shawn Malone

31 January 2021

Choroid plexus papilloma (CPP) is a rare brain tumour occurring mostly in infants and children. Most CPPs are intraventricular and present with symptoms and signs of increased intracranial pressure (ICP). This case report describes a middle-aged fema...

  • Article
  • Open Access
21 Citations
3,800 Views
10 Pages

Cost Minimization Analysis of Hypofractionated Radiotherapy

  • Hannah L. Yaremko,
  • Gordon E. Locke,
  • Ronald Chow,
  • Michael Lock,
  • Robert Dinniwell and
  • Brian P. Yaremko

30 January 2021

Early-stage breast cancer patients comprise a large proportion of patients treated with radiotherapy in Canada. Proponents have suggested that five-fraction hypofractionated radiotherapy for these patients would result in significant cost savings. An...

  • Article
  • Open Access
6 Citations
2,592 Views
9 Pages

Comparison of Up-Front Minimally Invasive Esophagectomy versus Open Esophagectomy on Quality of Life for Esophageal Squamous Cell Cancer

  • Zhenhua Li,
  • Jingge Cheng,
  • Yuefeng Zhang,
  • Shiwang Wen,
  • Huilai LV,
  • Yanzhao Xu,
  • Yonggang Zhu,
  • Zhen Zhang,
  • Donghui Mu and
  • Ziqiang Tian

25 January 2021

This study investigates whether minimally invasive esophagectomy (MIE) is a safe and effective way for patients with resectable esophageal cancer by comparing the short-term quality of life (QOL) after minimally invasive esophagectomy and open esopha...

of 10

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Curr. Oncol. - ISSN 1718-7729